Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Adial Pharmaceuticals Secures Expanded Patent for Genotype-Based Treatment of Alcohol Use Disorder

Adial Pharmaceuticals receives a patent for expanded genotype coverage in treating alcohol use disorder with its drug AD04.Quiver AI SummaryAdial Pharmaceuticals, a clinical-stage biopharmaceutical company...

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery

ADIL : 1.0700 (+1.90%)
Adial Pharmaceuticals Announces Topline Results For Onwardâ„¢ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an...

ADIL : 1.0700 (+1.90%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals to Announce Topline Results of ONWARDâ„¢ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder

Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET...

ADIL : 1.0700 (+1.90%)
ADILW : 0.0009 (-57.14%)

Barchart Exclusives

Is It Time to Sell This Second-Fiddle AI Stock Before 2025?
Bank of America has cut its rating on AMD while lowering its price target. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar